問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

Recruiting

List

1438Cases

2018-04-01 - 2028-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433

  • Condition/Disease

    Crohn's Disease

  • Test Drug

    Upadacitinib (ABT-494)

Participate Sites
5Sites

Recruiting3Sites

Terminated1Sites

周仁偉
China Medical University Hospital-Taipei

未分科

2018-04-01 - 2020-01-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy

  • Condition/Disease

    Moderately to Severely Active Crohn's Disease

  • Test Drug

    Upadacitinib (ABT-494)

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

2019-03-01 - 2026-12-31

Phase III

A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease

  • Condition/Disease

    Crohn’s Disease

  • Test Drug

    Ozanimod

Participate Sites
6Sites

Recruiting5Sites

2018-04-01 - 2020-04-01

Phase III

Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

  • Condition/Disease

    Crohn’s disease, CD

  • Test Drug

    Ozanimod

Participate Sites
6Sites

Recruiting5Sites

周仁偉
China Medical University Hospital-Taipei

未分科

2018-04-01 - 2020-04-01

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

  • Condition/Disease

    Crohn’s disease, CD

  • Test Drug

    Ozanimod

Participate Sites
6Sites

Recruiting5Sites

2018-06-01 - 2027-06-30

Phase II/III

A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease

  • Condition/Disease

    Moderately to Severely Active Crohn's Disease

  • Test Drug

    guselkumab

Participate Sites
4Sites

Recruiting4Sites

2017-01-01 - 2023-12-31

Phase I

A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

  • Condition/Disease

    Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

  • Test Drug

    Pralsetinib(BLU-667)

Participate Sites
2Sites

Recruiting2Sites

2020-06-16 - 2023-12-31

Phase III

A Randomized, Double-Blind, Phase III Study Comparing FTD/TPI Therapy Versus Placebo in Patients Who Are Positive for Blood Circulating Tumor DNA After Curative Resection of Colorectal Cancer

  • Condition/Disease

    Curative Resection of colorectal cancer

  • Test Drug

    LONSURF

Participate Sites
1Sites

Recruiting1Sites

1 140 141 142 143 144
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB